首頁 › 卵巢癌 › 俄亥俄州 › Cincinnati
Cincinnati, OH 的 卵巢癌 臨床試驗
19 項針對 卵巢癌 的研究正在 Cincinnati（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- Good Samaritan Hospital - Cincinnati, Cincinnati
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
招募中2 期
- University of Cincinnati Medical Center. /ID# 278925, Cincinnati
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
招募中2 期
- Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
招募中2 期
- Research Site, Cincinnati
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
招募中3 期
- University of Cincinnati Medical Center, Cincinnati
- Oncology Hematology Care Inc, Cincinnati
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
招募中3 期
- University of Cincinnati Medical Center ( Site 0042), Cincinnati
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
招募中3 期
- St Elizabeth Healthcare, Edgewood · 距離 8 英里
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
招募中2 期
- Oncology Hematology Care, Inc, Cincinnati
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
招募中1/2 期
- Christ Hospital, Cincinnati
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
招募中3 期
- University of Cincinnati Medical Center ( Site 0090), Cincinnati
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
招募中1 期
- St. Elizabeth Healthcare, Edgewood · 距離 8 英里
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
招募中
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- 還有 3 項
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
招募中3 期
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- 還有 1 項
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
招募中1/2 期
- Oncology Hematology Care Primary, Cincinnati
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
招募中2/3 期
- St. Elizabeth Medical Center, Edgewood · 距離 8 英里
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
招募中2 期
- St. Elizabeth Medical Center - Edgewood /ID# 272113, Edgewood · 距離 8 英里
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
招募中3 期
- University of Cincinnati Medical Center, Cincinnati
- TriHealth Cancer Institute - Good Samaritan Hospital, Cincinnati
- TriHealth Cancer Institute- Thomas Comprehensive Care Center, Cincinnati
- 還有 1 項
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Cincinnati
其他城市的 卵巢癌 試驗
- Houston, TX89 項研究
- New York City, NY69 項研究
- Boston, MA61 項研究
- Los Angeles, CA50 項研究
- Nashville, TN49 項研究
- Arlington, VA46 項研究
- Philadelphia, PA44 項研究
- Columbus, OH39 項研究
- St. Louis, MO38 項研究
- Chicago, IL36 項研究
- San Antonio, TX31 項研究
- Cleveland, OH30 項研究
Cincinnati 的其他研究
- 非小細胞肺癌35 項研究
- 癌症（所有類型）27 項研究
- 乳癌25 項研究
- 心臟衰竭24 項研究
- 大腸直腸癌21 項研究
- 轉移性癌症21 項研究
- 急性髓系白血病20 項研究
- 肥胖症19 項研究
- 肺癌19 項研究
- 前列腺癌18 項研究
- 黑色素瘤17 項研究
- 多發性骨髓瘤17 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。